Isodiol is furthering its position in the Pet Industry and is showcasing its All-Natural CBD Supplement Line, Pawceuticals at Pet EPPS
VANCOUVER, British Columbia, May 01, 2019 (GLOBE NEWSWIRE) -- Isodiol International Inc. (CSE: ISOL) (OTCQB:ISOLF) (FSE: LB6B.F) (the “Company” or “Isodiol”) is exhibiting at The Efficient Collaborative Retail Marketing Company (“ECRM”) Efficient Program Planning Sessions (“EPPS”): Pet EPPS, through May 01, 2019. This event also marks the debut of Pawceuticals, the Company’s CBD-based product line that naturally aids in restoring a pet’s health.
The EPPS within the ECRM event series allow vendors to have direct discussions with more than 80 retailers and other brands about business objectives, such as product launches, marketing campaigns, and more. The ECRM’s mission is to bring efficiencies to the buying and selling process by optimizing product assortments and enhancing supplier and buyer collaboration efforts through digital and in-person platforms.
At the Pet EPPS, suppliers of Branded & Private Brand Pet supplies, toys, grooming/health, food and treats are presenting and reviewing new programs, marketing initiatives and promotional opportunities to retailers across all channels.
“This is another step in the right direction for our retail effort strategy and we believe our All-Natural CBD-Supplement line, Pawceuticals, presents numerous opportunities in the Consumer Packaged Goods (CPG) market,” said CEO of Isodiol, Marcos Agramont. “As we move into the latter half of 2019, the Company will continue to build strong relationships with large retailers and focus on bringing its products to consumers across the United States and other international markets.”
About Isodiol International Inc.
Isodiol International Inc. is focused on the nutritional health benefits that are derived from hemp and is a product development, sales, marketing and distribution company of hemp-based Consumer Packaged Goods (CPG) and solutions. Isodiol has commercialized a 99%+ pure, naturally isolated CBD, including micro-encapsulations, and nano-technology for quality consumable and topical skin care products. The Company received approval for its CBD as an Active Pharmaceutical Ingredient (API) for use in Finished Pharmaceutical Products (FPPs), as was announced on April 26, 2018. Isodiol’s growth strategy includes the development of over-the-counter and pharmaceutical drugs and continued international expansion into Latin America, Asia, and Europe through the proliferation of its various brands, including the recently acquired CBD Naturals® portfolio of brands and proprietary technologies.
About Efficient Collaborative Retail Marketing Company, LLC
Efficient Collaborative Retail Marketing Company, LLC (ECRM) helps buyers and suppliers increase productivity, optimize product assortments and enhance collaboration efforts via its service offerings that include product discovery, category development and category planning. Over the past 20+ years, the company has grown to serve buyers and suppliers around the world in the following markets: grocery, general merchandise, health and beauty care, foodservice, and pharmacy/medical markets. For more information, please visit www.ecrm.marketgate.com.
ON BEHALF OF THE BOARD
Marcos Agramont, CEO & Director
Forward-Looking Information: This news release contains "forward-looking information" within the meaning of applicable securities laws relating to statements regarding the Company's business, proposed arrangement with creditors, products and future the Company’s business, its product offerings and plans for sales and marketing. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. Readers are cautioned not to place undue reliance on forward-looking information. Such forward-looking statements are subject to risks and uncertainties that may cause actual results, performance and developments to differ materially from those contemplated by these statements depending on, among other things, the risks that the Company's products and plan will vary from those stated in this news release and the Company may not be able to carry out its business plans as expected. Except as required by law, the Company expressly disclaims any obligation and does not intend, to update any forward-looking statements or forward-looking information in this news release. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct and makes no reference to profitability based on sales reported. The statements in this news release are made as of the date of this release.
The CSE has not reviewed, approved or disapproved the content of this press release.